Qiagen Continues Building PCR-Based Molecular Dx Menu with Johns Hopkins, Celera Deals | GenomeWeb

Qiagen this week inked a pair of deals intended to bolster its rapidly expanding portfolio of molecular diagnostic offerings.

In the first deal, announced earlier this week, Qiagen said that its recently acquired DxS subsidiary has obtained a worldwide exclusive license from Johns Hopkins University to develop real-time and endpoint PCR companion diagnostic assays based on the PI3K biomarker.

Under the second deal, announced today by Celera, Qiagen will distribute a Celera multiplex PCR-based assay for detecting respiratory pathogens.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.